Loading, Please Wait...
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Dr. Howard Levy, chief medical officer of Catalyst, will deliver an oral presentation at the 2018 Hemophilia Drug Development Summit being held in Boston on August 14-16, 2018.
|Presentation Title:||Subcutaneous Delivery of Coagulation Factors|
|Presenter:||Howard Levy, M.B.B.Ch., Ph.D., M.M.M.|
|Session:||Research & Development of Next Generation Prophylaxis|
|Date/Time:||Wednesday, Aug. 15, 2018 at 12:00 p.m. EDT|
A copy of the presentation materials can be accessed on the Events and Presentations section of the Catalyst website once the presentation concludes.
Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential for Catalyst’s product candidates, including its subcutaneously administered product candidates, to address hemophilia indications, and its plans to advance these product candidates. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, that human trials will not replicate the results from animal studies, that potential adverse effects may arise from the testing or use of the Company’s products, including the generation of antibodies, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, competition and other factors that affect our ability to establish collaborations on commercially reasonable terms and other risks described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 and with other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.
Fletcher Payne, CFO
Catalyst Biosciences, Inc.
Josephine Belluardo, Ph.D.
LifeSci Public Relations